Shock Therapeutics Biotech
STBI is an early-stage biopharmaceutical company founded to advance the development of a revolutionary medical discovery that could reverse the condition of shock, buying time for life-saving critical care interventions.
THE PROBLEM
Hypovolemic Shock (Hemorrhagic Shock or Shock) is the condition which precedes death in almost all cases of fatal injury & trauma.
The U.S.
Over 250,000
Leading cause of death under 45 annually killing
CDC
The World
4.4
Million
Annually injury and violence kill an estimated
WHO
The Military
Preventable
Deaths
Leading cause of potentially
Eastridge & Holcomb 2019
Unfortunately, once shock sets in, it is incredibly hard to reverse. We believe this is because the current treatment options are for the trauma and symptoms of shock - not for shock itself.